Structure of BAY-6672, a potent, selective and orally bioavailable prostanoid FP receptor antagonist

oral prostaglandin F receptor GCPR antagonist

to treat IPF, in vivo efficacy in fibrosis model

from ~3M cmpd cell-based HTS and opt.

J. Med. Chem., Oct. 22, 2020 issue

Bayer AG, Wuppertal, DE

BAY-6672 (Bayer oral in vivo prostaglandin F receptor GCPR antagonist)

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.